Toujeo, Perjeta Biosimilars On Biocon-Mylan Menu But Humira Version Iffy

Biocon is building on its alliance with Mylan and the partners are adding biosimilar programs for insulin glargine 300 units/mL and pertuzumab to their pipeline. But there's little clarity on the duo's ongoing program for biosimilar adalimumab in the backdrop of Mylan's recent deal with Fujifilm Kyowa Kirin Biologics for its product.

Success ladder leading to cloud and many short ones. Business, goal, competition, unique, progress, challenge, hope and leadership concept. EPS 8 vector illustration, no transparency — BIOCON AND MYLAN ARE ADDING PRODUCTS TO THEIR ALLIANCE

Biocon Ltd.and Mylan NV are expanding their long-running biosimilars collaboration to include two new next-generation biosimilar programs - insulin glargine 300 units/mL (Sanofi's Toujeo) and pertuzumab (Roche’s Perjeta) – but the Indian firm’s management was non-committal on the outlook for the duo’s own partnered Humira biosimilar.

Biocon said that the new programs would bolster their existing global biosimilars portfolio comprising antibodies and insulin analogs, though no...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

06 Jun 2025

• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

04 Jun 2025

• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

04 Jun 2025

• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.